DaeWoong Pharmaceutical Co., Ltd. will participate in the 'BIO KOREA 2018' held at COEX from May 9th(Wed.) to 11th(Fri.).
DaeWoong Pharmaceutical Co., Ltd. is a global health care group which was founded in 1945 with a belief of medicine patriotism that 'manufacturing good medicine protects the health of people and creates a healthy society'. With a strategy that 'DaeWoong Pharmaceutical company develops intensively medicine that nobody manufactures in the global market', they are full time contributing to developing new compound medicine and new biomedicine by investing continuously more than 10% of their annual sales each year in R&D. Their main business areas are Ethical The Counter drug(ETC), Over The Counter Drug(OTC) such as URSA and Impactamin tab, finished and raw material medicine export, and production on consignment.
Their main products are hospital prescription drugs(Olmetec tab, Crestor tab, Zemiglo tab) of chronic disease area such as high blood pressure, hyperlipidemia, and diabetes, Albis tab of antiulcer drugs in the product line of digestive organs, Impactamin tab, Easydem, and EZN6 as well as the main product of OTC, URSA. 'URSA', 'DaeWoong CoQ10', and 'NABOTA' have been globally recognized as the first-class products and the representative product, URSA, was selected as the World Class 300 in 2012. DaeWoong Pharmaceutical Company is aiming for overseas sales to exceed domestic sales through Daewoong Pharmaceutical Company's global success in 'Global 2020 Vision'.
In order to achieve the Global 2020 Vision, DaeWoong Pharmaceutical Company takes 'strengthening local market dominance' and 'open-strategical partnership' as the main strategies. Strengthening market dominance is a strategy that, in order to secure business sustainability in the overseas markets, their overseas corporation build, share and control business network with several cooperators after autonomously securing market access(license/insurance/medical fee/bid) capability, and at the same time, they strengthen their competitiveness with a strategy which is suitable for each country such as leading the marketing through direct management of core customers. 'Open-strategical partnership' is a market innovation strategy which increases sustainable competitiveness of the corporation through contact and cooperation with the persons concerned such as local regulators, policy institutions, experts, media, citizens, non-governmental organizations, etc., enhances a non-market strategy enhancing business opportunity factors through anticipative response of policy-directional and at the same time, enhances various partnership and cooperator business models such as co-promotion, joint venture, joint development, strategical investment and so on.
DaeWoong Pharmaceutical company is now opening several business models such as CDMO, joint investment, joint development, L/O, M&A, technology transfer etc. through open collaboration, and is trying to enter mainly to Asia, USA, Europe, the Middle East and CIS.
Meanwhile, the BIO KOREA 2018, which has been 13 years this year, is expected to have around 25 thousand visitors from 45 countries for Asia largest sized bio and health industry convention. At a total of 19 conference sessions including the development trend of immuno-anticancer medicine, visitors can directly see the new paradigm of global health and the future of the next generation global healthy industry. Specialized unit ev
ents(Invest Fair, MedTech Fair, Job Fair, MedLab etc.) as well as an exhibition which can be seen only at the BIO KOREA international convention will play a role of catalysts for quantitative and qualitative growth throughout international health industry such as strengthening the international competitiveness of pharmaceutical and medical device industries, creating jobs, in addition to the investment vitalization opportunity for experts of health industry.